<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763070</url>
  </required_header>
  <id_info>
    <org_study_id>5210</org_study_id>
    <nct_id>NCT04763070</nct_id>
  </id_info>
  <brief_title>Ciprofloxacin in Drug-resistant Epilepsy</brief_title>
  <acronym>CIDRE</acronym>
  <official_title>Effect of Ciprofloxacin on Seizure Frequency in Patients With Drug-resistant Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of a short-term prescription of ciprofloxacin on&#xD;
      intestinal microbial pattern and seizure frequency of patients with drug-resistant epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in seizure frequency registered in questionnaire</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of seizure frequency in 4th week with the frequency at the start of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in quantity of microbial DNA extracted from stool samples by AccuPrep Stool DNA extraction Kit</measure>
    <time_frame>7 days</time_frame>
    <description>Comparison of quantity of extracted microbial DNA in stool sample taken at day5-7 with the sample taken at the start of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in microbial burden of stool samples using Absolute real time polymerase chain reaction (PCR)</measure>
    <time_frame>7 days</time_frame>
    <description>Comparison of microbial burden of stool samples taken at day5-7 with the sample taken at the start of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in seizure frequency registered in questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of seizure frequency in 12th week with the frequency at the start of the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Epilepsy Intractable</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin Oral Product</intervention_name>
    <description>The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Drug-resistant epilepsy with frequency of at least 2 seizure/Week&#xD;
&#xD;
          -  Acceptance of patients or his/her guardian (Signing informed consent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to ciprofloxacin or other fluoroquinolones&#xD;
&#xD;
          -  History of tendon, renal, hepatic or cerebrovascular disease, organ transplantation or&#xD;
             myasthenia gravis&#xD;
&#xD;
          -  Usage of medications with interaction to ciprofloxacin&#xD;
&#xD;
          -  No reliable contraception&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Being under treatment with corticosteroid&#xD;
&#xD;
          -  Usage of antibiotics in recent 2 months or need to use it during the study&#xD;
&#xD;
          -  Patients who are candidate for epilepsy surgery or other nonmedical treatments&#xD;
&#xD;
          -  Change in anti-seizure medications (ASMs) during recent month&#xD;
&#xD;
          -  Patients who will need changes in ASMs dose during study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bu Ali Sina hospital</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <zip>4815838477</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Nasim Tabrizi</investigator_full_name>
    <investigator_title>Associate professor of neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

